Merck & Co. Inc. (MRK)

82.78
NYSE : Health Technology
Prev Close 82.35
Day Low/High 82.46 / 83.37
52 Wk Low/High 59.80 / 84.27
Avg Volume 10.26M
Exchange NYSE
Shares Outstanding 2.57B
Market Cap 213.44B
EPS 2.30
P/E Ratio 48.20
Div & Yield 2.20 (2.46%)
Drugs, Defense, Shutdown, China: Trump's State of the Union Speech

Drugs, Defense, Shutdown, China: Trump's State of the Union Speech

Dramatic showdown or appeal for unity? Trump seeks to 'heal old wounds, build new coalitions.'

'Wonder Dogs' and 'Underdogs': 2 Hot Diggity Twists on the 'Dogs of the Dow'

'Wonder Dogs' and 'Underdogs': 2 Hot Diggity Twists on the 'Dogs of the Dow'

Selecting the creme de la creme of last year's top dividend dogs generated an average total return of 8.8%.

Merck Is Named No. 1 Pharma Pick at Bank of America

Merck Is Named No. 1 Pharma Pick at Bank of America

Strong sales of key cancer treatment drug Keytruda are expected to continue to drive revenues and earnings.

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) In Combination With Chemotherapy For First-Line Treatment Of Adults With Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) In Combination With Chemotherapy For First-Line Treatment Of Adults With Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending KEYTRUDA, Merck's...

Dow and S&P Hold on to Slim Gains While Amazon Drags Nasdaq Into the Red

Dow and S&P Hold on to Slim Gains While Amazon Drags Nasdaq Into the Red

The Dow Jones Industrial Average rose Friday as the U.S. economy creates nearly double the expected number of jobs in January and investors weigh the progress of trade talks between Washington and Beijing.

Merck Tops Q4 Earnings, Guides for Solid 2019, as Keytruda Sales Pass $2 Billion

Merck Tops Q4 Earnings, Guides for Solid 2019, as Keytruda Sales Pass $2 Billion

Merck posted moderately stronger-than-expected fourth quarter earnings Friday, and issued robust profit guidance for 2019, as sales of its key Keytruda cancer drug topped estimates.

The Global Macro-Economic Picture, China Watch, Keys to Amazon: Market Recon

The Global Macro-Economic Picture, China Watch, Keys to Amazon: Market Recon

The real takeaway for AMZN for me, and the main reason that I am even in the name on a semi-permanent basis, is AWS.

Amazon, Jobs Report, Exxon Mobil and Honeywell - 5 Things You Must Know

Amazon, Jobs Report, Exxon Mobil and Honeywell - 5 Things You Must Know

U.S. stock futures are lowerFriday as investors weigh the progress of trade talks between Washington and Beijing and await a reading on U.S. jobs; Amazon falls after issuing first-quarter guidance below expectations; Exxon Mobil, Chevron and Honeywell report earnings.

Financial Highlights Package

Financial Highlights Package

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2018.

Friday Earnings Preview: Cigna, Merck, Exxon, Honeywell All Report

Friday Earnings Preview: Cigna, Merck, Exxon, Honeywell All Report

The week will end with four notable earnings reports, namely from Cigna and Merck.

Merck Receives Breakthrough Therapy Designation From FDA For V114, The Company's Investigational 15-Valent Conjugate Vaccine For The Prevention Of Invasive Pneumococcal Disease, In Infants, Children, And Adolescents

Merck Receives Breakthrough Therapy Designation From FDA For V114, The Company's Investigational 15-Valent Conjugate Vaccine For The Prevention Of Invasive Pneumococcal Disease, In Infants, Children, And Adolescents

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that V114, the company's investigational 15-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.

Mary Ellen Coe Elected To Merck Board Of Directors

Mary Ellen Coe Elected To Merck Board Of Directors

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Mary Ellen Coe, president, Google Customer Solutions, at Google Inc.

Merck Announces Second-Quarter 2019 Dividend

Merck Announces Second-Quarter 2019 Dividend

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #7 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #93 spot out of 500.

The Technical Oracle of Delphi Says Merck Could Go Up or Down

The Technical Oracle of Delphi Says Merck Could Go Up or Down

How do the charts and indicators look ahead of their quarterly release?

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

Jim Cramer's plan for getting through the heart of earnings season next week.

How to Trade Merck and Pfizer Pre-Earnings - Each Face Deteriorating Charts

How to Trade Merck and Pfizer Pre-Earnings - Each Face Deteriorating Charts

Merck and Pfizer have been laggards so far in 2019. Technical warnings occurred on Dec. 4 when both set multiyear highs and both received downgrades.

The Market Starts Rotating: Cramer's 'Mad Money' Recap (Thursday 1/24/19)

The Market Starts Rotating: Cramer's 'Mad Money' Recap (Thursday 1/24/19)

Thursday's market action showed signs investors are moving away from safety plays, Jim Cramer says.

Merck KGaA, Darmstadt, Germany, Grants Exclusive License To Vertex For Two DNA Damage Response Inhibitors

Merck KGaA, Darmstadt, Germany, Grants Exclusive License To Vertex For Two DNA Damage Response Inhibitors

DARMSTADT, Germany, January 24, 2019 /PRNewswire/ -- Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas    Merck KGaA, Darmstadt, Germany retains...

Merck To Hold Fourth-Quarter And Full-Year 2018 Sales And Earnings Conference Call On February 1

Merck To Hold Fourth-Quarter And Full-Year 2018 Sales And Earnings Conference Call On February 1

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Big pharma is shaping up to be a consolidating category in 2019.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Merck's KEYTRUDA® (pembrolizumab) Reduced Risk Of Death By 31 Percent Compared To Chemotherapy In Previously Treated Patients With Advanced Esophageal Or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)

Merck's KEYTRUDA® (pembrolizumab) Reduced Risk Of Death By 31 Percent Compared To Chemotherapy In Previously Treated Patients With Advanced Esophageal Or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from KEYNOTE-181, a Phase 3 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy for the second-line treatment of...

Moderna Shares Jump on Positive Cancer-Treatment Progress

Moderna Shares Jump on Positive Cancer-Treatment Progress

Report on positive results of new drugs to treat ovarian and other cancers sends shares higher.

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Jim Cramer talks about the Fed, and outlines your game plan.

Jim Cramer: Best and Worst of the Dow in 2018

Jim Cramer: Best and Worst of the Dow in 2018

And which stocks are still a buy into 2019.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.

TheStreet Quant Rating: A- (Buy)